Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 12:16:1591631.
doi: 10.3389/fimmu.2025.1591631. eCollection 2025.

Ruxolitinib in adult dermatomyositis with anti-TIF1γ antibody: a case report and literature review

Xu Jing  1 , Wang Min  2 , Liu Xia  3 , Li Shanshan  3
Affiliations
Review

Ruxolitinib in adult dermatomyositis with anti-TIF1γ antibody: a case report and literature review

Xu Jing et al. Front Immunol. .

Abstract

Ruxolitinib is a selective JAK1/2 inhibitor, and its application in treating adult-onset dermatomyositis(DM) has rarely been described. Here, we report a case of an adult-onset DM patient with anti-TIF1γ antibody, who also suffered from essential thrombocytosis related to the JAK2 V617F mutation. Her clinical symptoms of DM markedly improved after ruxolitinib treatment, whereas her platelet count did not significantly change. In addition, we reviewed previous studies on the treatment of adult DM with ruxolitinib, and summarized reports of the JAK2 V617F mutation in adult idiopathic inflammatory myopathy.

Keywords: JAK2 V617F mutation; anti-TIF1γ antibody; dermatomyositis; essential thrombocytosis; ruxolitinib.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer KT declared a shared parent affiliation with the author JX to the handling editor at the time of review.

Figures

Figure 1
Figure 1
the clinical feature of patient with DM and ET. (a) the rash before ruxolitinib. (b) the T2 MRI of lower limb before ruxolitinib. (c) the rash after ruxolitinib at 5th month. (d) the change of platelet count (blue arrow: ruxolitinib start).
See this image and copyright information in PMC

References

    1. Lv Y, Qi J, Babon JJ, Cao L, Fan G, Lang J, Zhang J, et al. The JAK-STAT pathway: from structural biology to cytokine engineering. Signal Transduct Target Ther. (2024) 9:221. doi: 10.1038/s41392-024-01934-w - DOI - PMC - PubMed
    1. Beckett M, Tan J, Bonnardeaux E, Dutz J, Shojania K, To F, et al. Tofacitinib therapy in refractory inflammatory myositis: a retrospective cohort study of 41 patients. Rheumatol (Oxford). (2024) 63:1432–6. doi: 10.1093/rheumatology/kead404 - DOI - PubMed
    1. Harada H, Shoda H, Tsuchiya H, Misaki M, Sawada T, Fujio K. Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease. Rheumatol Int. (2024) 44:961–71. doi: 10.1007/s00296-024-05551-2 - DOI - PMC - PubMed
    1. Beckett M, Dutz J, Huang K. Upadacitinib therapy in refractory inflammatory myositis: a case series of 10 patients. RMD Open. (2024) 10:e003837. doi: 10.1136/rmdopen-2023-003837 - DOI - PMC - PubMed
    1. Wu W, Guo B, Sun W, Chen D, Xu W, Chen Z, et al. Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multi-center cohort study. Eur Respir J. (2025) 65:2401488. doi: 10.1183/13993003.01488-2024 - DOI - PMC - PubMed

LinkOut - more resources